The European Union approves a drug that slows the progression of type 1 diabetes.

The European Commission has authorized the marketing of the drug “Tizild,” which slows the progression of type 1 diabetes, within the European Union, according to an announcement by the French company (Sanofi), the drug’s manufacturer.

The company said in a statement that this license makes Tizeld the first treatment that affects the progression of type 1 diabetes to receive formal approval in the European Union.

The approval includes the use of the drug in adults and children over the age of eight with stage 2 type 1 diabetes.

The drug is given via intravenous infusion and does not cure the disease, but it slows its progression by suppressing the autoimmune response.

The drug is used when the disease is detected and before clinical symptoms appear, thus delaying its progression to the third stage, which requires insulin treatment to control blood sugar levels.

The manufacturer explained that the European Commission’s decision was based on the positive results of the “TN-10” study, which showed that the monoclonal antibody “Tizild” was able to delay the onset of type 1 diabetes for an average of nearly two years compared to a placebo.

According to the study results, the percentage of patients who remained in the second stage of the disease was 57% in the “Tizild” group compared to 28% in the placebo group.

The drug “Tizild” has previously received regulatory approvals in the United States, the United Kingdom, China, Canada, Israel, Saudi Arabia, the United Arab Emirates and Kuwait.